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Abstract

Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we
established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled to
date (the Genome Research in African American Scleroderma Patients (GRASP) cohort).
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African American SSc patients were enrolled retrospectively and prospectively over a 30-year period (1987–2016), from 18
academic centers throughout the United States. The cross-sectional prevalence of sociodemographic, clinical, and serological
features was evaluated. Factors associated with clinically signiﬁcant manifestations of SSc were assessed using multivariate logistic
regression analyses.
The study population included a total of 1009 African American SSc patients, comprised of 84% women. In total, 945 (94%)
patients met the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classiﬁcation
criteria for SSc, with the remaining 64 (6%) meeting the 1980 ACR or CREST (calcinosis, Raynaud’s phenomenon, esophageal
dysmotility, sclerodactyly, telangiectasia) criteria. While 43% were actively employed, 33% required disability support. The majority
(57%) had the more severe diffuse subtype and a young age at symptom onset (39.1 ± 13.7 years), in marked contrast to that
reported in cohorts of predominantly European ancestry. Also, 1 in 10 patients had a severe Medsger cardiac score of 4. Pulmonary
ﬁbrosis evident on computed tomography (CT) chest was present in 43% of patients and was signiﬁcantly associated with antitopoisomerase I positivity. 38% of patients with CT evidence of pulmonary ﬁbrosis had a severe restrictive ventilator defect, forced
vital capacity (FVC) 50% predicted. A signiﬁcant association was noted between longer disease duration and higher odds of
pulmonary hypertension, telangiectasia, and calcinosis. The prevalence of potentially fatal scleroderma renal crisis was 7%, 3.5 times
higher than the 2% prevalence reported in the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR)
cohort.
Our study emphasizes the unique and severe disease burden of SSc in African Americans compared to those of European
ancestry.
Abbreviations: ACE = angiotensin converting enzyme, ACR/EULAR = American College of Rheumatology/European League

Against Rheumatism, ANA = antinuclear antibody, ANOVA = analysis of variance, CI = conﬁdence interval, CREST = calcinosis, CT =
computed tomography, dcSSc = diffuse cutaneous systemic sclerosis, DLCO = diffusing capacity of the lung for carbon monoxide,
esophageal dysmotility, EUSTAR = European League Against Rheumatism Scleroderma Trials and Research, EUSTAR = European
League Against Rheumatism Scleroderma Trials and Research, FVC = forced vital capacity, GRASP = Genome Research in African
American Scleroderma Patients cohort, ILD = interstitial lung disease, lcSSc = limited cutaneous systemic sclerosis, mRSS =
modiﬁed Rodnan Skin Score, Musculoskeletal and Skin Diseases, NIAMS = National Institute of Arthritis, NIH = National Institutes of
Health, OR = odds ratio, PFTs = pulmonary function tests, Raynaud’s phenomenon, RP = Raynaud’s phenomenon, sclerodactyly,
SLE = systemic lupus erythematosus, SRC = scleroderma renal crisis, SSc = systemic sclerosis, telangiectasia, US = United States.
Keywords: African Americans, autoantibodies, systemic sclerosis

database and signiﬁcant size of the GRASP cohort provides
adequate statistical power to perform informative multivariate
analyses.
In this paper, we describe the clinical and serological
characteristics of the GRASP cohort and report the results of
multivariate analyses, to identify factors associated with clinically
signiﬁcant and severe manifestations of SSc in African Americans.
Additionally, we compare the ﬁndings in the GRASP cohort to
that reported in a multicenter cohort of predominantly European
ancestry.

1. Introduction
There is evidence that racial differences exist in the susceptibility
to and severity of systemic sclerosis (scleroderma; SSc). African
Americans have a higher age-speciﬁc incidence and prevalence of
SSc compared to European Americans.[1,2] Moreover, the most
current national report of SSc-associated mortality in the United
States (US) noted death rates that peaked a decade earlier in
the African American population, with age-adjusted mortality
signiﬁcantly higher in African Americans compared to European
Americans.[3]
The leading cause of mortality in SSc is attributed to
pulmonary complications, which occur in 70% to 90% of
patients.[4] The 10-year survival for SSc patients with interstitial
lung disease (ILD) is only 60%.[5] African ancestry is an
independent predictor of lung involvement in SSc.[6] Furthermore, the incidence of SSc-associated severe ILD[7] and
pulmonary hypertension[8,9] is reported to be higher in African
Americans than other ethnic groups.
Socioeconomic factors and impaired access to health care have
not fully accounted for the predilection of African Americans to poor
health outcomes.[10] Attempts to elucidate the factors inﬂuencing
increased disease severity have been hindered by the relatively small
size of available African American SSc cohorts.[11,12]
Accordingly, a multicenter SSc cohort database, the Genome
Research in African American Scleroderma Patients (GRASP)
clinical database, was established to enhance our understanding
of the phenotype of SSc in African Americans and identify factors
contributing to the severity of their disease. The GRASP cohort
consists of more than 1000 extensively phenotyped African
American SSc patients enrolled from academic centers throughout the US. It is currently the largest multicenter cohort of African
American SSc patients. Consequently, the comprehensive clinical

2. Methods
2.1. Study population
The GRASP clinical database was established in May 2013 and
includes socio-demographic and clinical characteristics of a US
cohort of exclusively African American SSc patients, enrolled
retrospectively and prospectively over a 30-year period (1987–
2016). African American race was ascertained by patient selfidentiﬁcation. All patients met the 1980 American College of
Rheumatology (ACR) or 2013 ACR/EULAR (European League
Against Rheumatism) classiﬁcation criteria for systemic sclerosis;
or had at least 3 of 5 features of the CREST (calcinosis,
Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly,
telangiectasia) syndrome.[13,14]
2.2. Study protocol
Patients were enrolled from a total of 18 academic centers
throughout the US. The study was conducted in accordance with
the Declaration of Helsinki[15] and participating centers secured
local ethics committee approval prior to participant enrollment.
2
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(ANOVA) as appropriate. Factors associated with clinical
manifestations of SSc and severe organ involvement were
identiﬁed using multivariable logistic regression analyses including covariates: sex (male versus female), SSc subtype (dcSSc
versus lcSSc), SSc-associated autoantibody status (anti-centromere, anti-topoisomerase I or anti-RNA polymerase III positivity), age at ﬁrst symptom onset and disease duration in years.
These variables were ﬁxed in all analyses because of their clinical
relevance.
The date of onset of the ﬁrst symptom attributed to SSc
(Raynaud’s or non-Raynaud’s) was used to calculate disease
duration. Sensitivity analyses were performed to ensure the
choice of disease onset (Raynaud’s onset versus ﬁrst nonRaynaud’s symptom onset) did not impact the magnitude or
signiﬁcance of observed associations with relevant clinical
outcomes. The covariate of smoking status (ever versus never
smoked cigarettes) was included in multivariable logistic
regression analysis to determine factors associated with vascular
and cardiopulmonary involvement. Assumptions in the statistical
analyses were veriﬁed using normal probability and leverage
plots. Statistical signiﬁcance was deﬁned as a 2-sided P value 
.05. The dataset was analyzed using Stata Statistical Software
version 14.2 (College Station, TX).

GRASP investigators documented clinical, serological and sociodemographic data, including age, sex, dates of SSc diagnosis and
symptom onset, smoking status, immunosuppressive medication
use, history of malignancy and autoantibody status. The presence
of an overlapping autoimmune disease (rheumatoid arthritis,
systemic lupus erythematosus, inﬂammatory myopathy, Sjögren’s syndrome) was ascertained based on established classiﬁcation criteria.[16–20]
Data from diagnostic studies including pulmonary function
tests (PFTs), echocardiograms, chest radiographs, and highresolution computed tomography (CT) scans of the chest and
right heart cardiac catheterizations were obtained. All data were
subsequently assembled in a clinical database, maintained at the
Johns Hopkins University coordinating site.
Disease onset was deﬁned as the occurrence of the ﬁrst ever
symptom attributed to SSc (Raynaud’s or non-Raynaud’s).
Disease duration was deﬁned as the time from disease onset to the
date of sample collection for genetic analysis. SSc subtype was
classiﬁed as diffuse (dcSSc) or limited (lcSSc) based on the extent
of cutaneous involvement, as described by LeRoy et al.[21]
Patients were classiﬁed as having diffuse SSc if there was clinical
evidence of cutaneous ﬁbrosis extending proximal to the elbows
or knees, at any time during the disease course.
The pattern of skin involvement was further classiﬁed into 4
subsets (Type 0,1,2,3) as previously deﬁned by Cottrell et al.[22]
The degree of cutaneous ﬁbrosis was quantitatively assessed
using the physician assigned modiﬁed Rodnan Skin Score
(mRSS).[23] The maximum mRSS and worst ever organ speciﬁc
severity scores were recorded for each patient. Organ-speciﬁc
severity scores were assigned in accordance with the revised
Medsger Severity Score for SSc.[24]
Target organ involvement was deemed to be present if the
respective Medsger Severity Score was ≥ 1. Severe organ
involvement was deﬁned as a Medsger Severity Score of 3
(severe) or 4 (end stage).[24] Accordingly, severe peripheral
vascular involvement was deﬁned as the presence of digital tip
ulcerations or digital gangrene. An mRSS ≥30 was indicative of
severe cutaneous involvement. Severe gastrointestinal disease
included malabsorption syndrome, episodes of pseudo-obstruction or the requirement of total parenteral nutrition. For renal
disease, severe involvement was deﬁned by a serum creatinine
level ≥3.0 mg/dL, or the requirement for dialysis or renal
transplant. Skeletal muscle involvement was deemed to be severe
if proximal muscle weakness with less than grade 3/5 power was
evident on physical examination, or the patient required
ambulation aids. Severe cardiac disease was deﬁned as a left
ventricular ejection fraction <40%, clinical signs of heart failure,
an arrhythmia requiring treatment, or heart transplant. Severe
pulmonary involvement was characterized by the presence of at
least one of the following: forced vital capacity (FVC) < 50% of
predicted, diffusing capacity of the lung for carbon monoxide
(DLCO) < 50% of predicted, moderate to severe pulmonary
hypertension, requirement for oxygen due to SSc-associated
pulmonary disease or lung transplant.

3. Results
3.1. Patient characteristics and sociodemographic
features
As of November 2016, a total of 1009 African American SSc
patients were enrolled in the GRASP cohort from the 18
participating US academic centers (Supplementary Table 1,
http://links.lww.com/MD/C23). Comprehensive clinical and
serological data were provided for most patients (Supplementary
Table 2, http://links.lww.com/MD/C23). The sociodemographic
features of the GRASP cohort are summarized in Table 1.
There was a female predominance, 843 (84%) women. The
majority of patients were insured. More than 50% completed a
college or post-graduate education. While 43% were actively
employed, 33% required disability support. At the time of study
enrollment, 35% of patients had a history of or currently smoked
cigarettes.
3.2. Disease characteristics
In total 94% patients met the 2013 ACR/EULAR classiﬁcation
criteria for SSc, with the remaining 6% meeting the 1980 ACR or
CREST criteria (Table 2). The majority of patients (57%) were
classiﬁed as dcSSc.
The mean age at SSc diagnosis was 42.4 ± 13.5 years, with an
average time to diagnosis of 3.4 ± 6.0 years from the onset of the
ﬁrst symptom attributed to SSc. The mean age at onset of the ﬁrst
symptom attributed to SSc was 39.1 ± 13.7 years (Table 2).
An assessment of the general health status was scored by
the Medsger general severity scale, which uses weight loss
and hematologic measures to deﬁne disease burden.[24]
10% exhibited a severe grade 4 disease burden, with weight
loss ≥44 pounds or anemia with hematocrit <25% (Fig. 1).

2.3. Statistical analysis
The cross-sectional prevalence of clinical and serological features
in the GRASP cohort was determined using the data obtained at
the time of study enrollment. Clinical and socio-demographic
characteristics were compared between groups based on sex,
serological proﬁle, and SSc subtype respectively, using t-test, chisquare test, Fisher’s exact test, and one-way analysis of variance

3.3. Organ involvement
3.3.1. Cutaneous. A high prevalence of diffuse disease (57%)
was noted, and a predilection for the diffuse subtype was
observed in both men and women (Table 2). The mean maximum
3
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mRSS for patients with dcSSc was 20 ± 10, and 5 ± 5 in patients
with lcSSc (Table 3). Anti-topoisomerase I (adjusted odds ratio
[OR] 1.67, 95% conﬁdence interval [95% CI] 1.08–2.58) and
anti-RNA polymerase III (adjusted OR 2.54, 95% CI 1.36–4.75)
positivity were signiﬁcantly associated with the diffuse subtype,
whereas anti-centromere positivity was found to be protective
(adjusted OR 0.14, 95% CI 0.05–0.38) (Table 4).
In bivariate analyses, higher mRSS values were associated with
male sex (difference in mRSS 4, P < .001), anti-topoisomerase I
positivity (difference in mRSS 4, P < .001) and anti-RNA
polymerase III positivity (difference in mRSS 7, P < .001).
Conversely, anti-centromere antibody positivity was associated
with lower mRSS values (difference in mRSS 8, P < .001). In
multivariate analyses, severe cutaneous involvement (mRSS ≥ 30)
was signiﬁcantly associated with male sex, anti-topoisomerase I,
and anti-RNA polymerase III positivity (Table 5).
50% of the GRASP cohort had telangiectasia (Table 2). In the
adjusted models, the relative odds of having telangiectasia was
4% higher for each year of disease duration and anti-RNA
polymerase III positivity was associated with over 50% lower
odds of exhibiting telangiectasia (Table 4).
18% of patients had a history of calcinosis. Longer disease
duration was the only factor signiﬁcantly associated with
calcinosis (Table 4).

Table 1
Socio-demographic characteristics of the Genome Research in
African American Scleroderma Patients cohort.
Socio-demographic characteristics

Number, %

Sex
Male
Female
Hispanic/Latino Ethnicity
Insurance
None
Medicare
Medical Assistance
Self-pay
Private
Marital status
Single
Divorced
Separated
Widowed
Domestic partnership
Married
Education
Grade school
Technical/trade
High school
College
Post-graduate
Employment
Unemployed
Employed
Disability
Retired
Cigarette use
Age at commencement, mean ± SD
Age at cessation, mean ± SD
Past PPD, mean ± SD
Current PPD, mean ± SD.

166 (16)
843 (84)
13 (2)
9
67
69
11
415

(2)
(12)
(12)
(2)
(73)

269
124
20
42
6
355

(33)
(15)
(2)
(5)
(1)
(44)

16
36
197
266
89

(3)
(6)
(33)
(44)
(15)

3.3.2. Raynaud’s phenomenon. The mean age at onset of
Raynaud’s phenomenon (RP) was 39.1 ± 13.5 years (Table 2).
98% of patients reported a history of RP. 31% of patients
experienced digital tip ulcerations and 6% reported complications of digital gangrene. Diffuse disease and cigarette smoking
were signiﬁcantly associated with severe vascular complications
of digital ulcers and gangrene (Table 5). Older age at symptom
onset was associated with signiﬁcantly lower odds of experiencing these severe vascular complications (Table 5).

77 (11)
297 (43)
224 (33)
87 (13)
331 (35)
20.4 ± 7.6
37.7 ± 13.5
0.7 ± 0.5
0.7 ± 0.4.

PPD = packs per day, SD = standard deviation.

Table 2
Clinical and serological characteristics of the Genome Research in African American Scleroderma Patients cohort by sex.
African American scleroderma patients
Female (n = 843)
Male (n = 166)

Total (n = 1009)
∗

ACR/EULAR 2013 criteria fulﬁlled
Age at symptom onset, mean ± SD
Raynaud’s Phenomenon
Non-Raynaud’s Phenomenon
Age at diagnosis, mean ± SD
Age at sample collection, mean ± SD
Disease duration, years, mean ± SD
Scleroderma phenotype
SSc Subtype
Limited
Diffuse
SSc Type
0
1
2
3
Maximum mRSS, mean ± SD
Raynaud’s Phenomenon
Telangiectasia
Calcinosis
Organ system involvement
Skin
Skeletal muscles
Myopathy
Elevated muscle enzymes
EMG evidence
MRI evidence
Biopsy proven
GI tract
Heart
Kidney

945 (94)
39.1 ± 13.7
39.1 ± 13.5
40.6 ± 13.4
42.4 ± 13.5
49.1 ± 12.9
9.9 ± 8.7

789 (94)
38.6 ± 13.7
38.8 ± 13.6
40.3 ± 13.4
42.2 ± 13.6
49.0 ± 13.0
10.3 ± 8.9

P

156 (95)
41.7 ± 13.4
41.1 ± 13.2
42.3 ± 13.1
43.7 ± 13.0
49.6 ± 12.0
8.0 ± 7.4

NA
.009
.052
.096
.196
.571
.002
.001

432 (43)
566 (57)

380 (46)
454 (54)

52 (32)
112 (68)

34 (3)
304 (30)
94 (9)
566 (57)
14 ± 11
975 (98)
503 (50)
184 (18)

31 (4)
269 (32)
80 (10)
441 (54)
13 ± 11
819 (98)
424 (51)
160 (19)

3 (2)
35 (21)
14 (9)
112 (68)
17 ± 12
156 (96)
79 (48)
24 (15)

<.001
.064
.487
.155

884 (96)
237 (28)

731 (95)
198 (28)

153 (98)
39 (27)

.130
.822

150
42
23
36
903
220
140

122
33
18
28
756
169
101

28
9
5
8
147
51
39

(23)
(7)
(4)
(6)
(94)
(24)
(15)

(23)
(7)
(4)
(6)
(94)
(22)
(13)

(24)
(8)
(5)
(7)
(94)
(34)
(25)

.009

.841
.579
.640
.524
.848
.002
<.001

(continued )
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Table 2
(continued).
African American scleroderma patients
Female (n = 843)
Male (n = 166)

Total (n = 1009)
SSc Renal Crisis
Pulmonary
FVC% pred, mean ± SD
DLCO% pred, mean ± SD
Pulmonary Fibrosis
CXR evidence
CT Chest evidence
and FVC 50% pred
Pulmonary Hypertension
ECHO PH
Cath PH
Autoantibodies
Anti-centromere
Anti-topoisomerase I
Anti-RNA polymerase III
Anti-U1 RNP
Anti-U3 RNP
Anti-Th/To
Anti-PmScl
Anti-Smith
Anti-Ro
Anti-La
Anti-dsDNA
Antinuclear
ANA pattern
Centromere
Homogenous
Nucleolar
Speckled
Cytoplasmic
Diffuse
Mixed
Overlapping disease
Rheumatoid arthritis
Systemic lupus erythematosus
Inﬂammatory myopathy
Sjögren’s syndrome
Other
Cancer
Comorbid conditions
CAD
ASCVD
Hypertension
Hyperlipidemia
Diabetes mellitus
COPD
Immunosuppressive medications
None
Prednisone
Methotrexate
Azathioprine
Cyclophosphamide
Mycophenolate mofetil
Hydroxycholoroquine
D-Penicillamine
Minocycline
Colchicine
Anti-tumor necrosis factor
Leﬂunomide
Intravenous immunoglobulin
Rituximab

56 (7)
839 (88)
62.6 ± 21.3
49.4 ± 21.7
563 (68)
88 (14)
360 (43)
131 (38)
282 (30)
189 (20)
167 (18)

43 (6)
699 (88)
63.0 ± 21.4
49.9 ± 21.2
463 (68)
66 (12)
293 (43)
103 (37)
230 (29)
157 (20)
137 (18)

72
270
79
142
18
5
7
50
137
27
47
898

(8)
(30)
(13)
(18)
(14)
(8)
(6)
(6)
(17)
(3)
(9)
(94)

68 (10)
213 (28)
67 (13)
120 (18)
16 (16)
5 (10)
7 (7)
44 (7)
119 (17)
24 (4)
39 (9)
750 (94)

48
69
268
226
2
5
127
204
37
64
87
14
16
36

(6)
(9)
(36)
(30)
(0.3)
(0.7)
(17)
(20)
(4)
(6)
(9)
(1)
(2)
(5)

46
58
227
186
2
3
102
177
36
64
70
11
10
30

45
27
368
122
65
46

(6)
(4)
(46)
(17)
(8)
(6)

176
473
186
72
113
321
227
42
14
29
24
10
27
25

(21)
(53)
(22)
(9)
(13)
(37)
(27)
(5)
(2)
(3)
(3)
(1)
(3)
(3)

13 (9)
140 (89)
60.7 ± 20.8
46.8 ± 23.9
100 (70)
22 (19)
67 (47)
28 (44)
52 (34)
32 (21)
30 (20)

P
.144
.870
.222
.113
.570
.064
.356
.242
.242
.790
.499
.008
.017
.726
.818
.526
.582
.342
.417
.318
.602
.907
.970
.104

4
57
12
22
2
0
0
6
18
3
8
148

(3)
(38)
(12)
(17)
(8)
(0)
(0)
(5)
(14)
(2)
(9)
(94)

(7)
(9)
(36)
(30)
(0.3)
(0.5)
(16)
(21)
(4)
(8)
(8)
(1)
(1)
(5)

2
11
41
40
0
2
25
27
1
0
17
3
6
6

(2)
(9)
(34)
(33)
(0.0)
(1.7)
(21)
(16)
(0.6)
(0)
(10)
(2)
(4)
(5)

.165
.021
<.001
.416
.713
.022
.822

32
25
302
99
52
33

(5)
(4)
(45)
(16)
(8)
(5)

13
2
66
23
13
13

(11)
(2)
(49)
(20)
(10)
(11)

.018
.208
.408
.321
.363
.026

143
401
161
65
83
259
206
37
11
23
23
10
22
22

(21)
(54)
(23)
(9)
(12)
(36)
(29)
(5)
(2)
(3)
(3)
(1)
(3)
(3)

33
72
25
7
30
62
21
5
3
6
1
0
5
3

(24)
(48)
(18)
(5)
(21)
(43)
(15)
(4)
(2)
(4)
(1)
(0)
(4)
(2)

.347
.190
.224
.120
.002
.125
.001
.437
.602
.524
.100
.160
.766
.547

Except where indicated otherwise, values are the number (%) of patients.
∗
The remaining met ACR 1980 or CREST criteria.
ANA = antinuclear antibody, ASCVD = atherosclerotic cardiovascular disease, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, CT = computed tomography, CXR = chest x-ray,
DLCO% pred = diffusing capacity of the lung for carbon monoxide percent of predicted, ECHO = echocardiogram, EMG = electromyogram, FVC% pred = forced vital capacity percent of predicted, MRI = magnetic
resonance imaging, mRSS = modiﬁed Rodnan skin score, PH = pulmonary hypertension, SSc = systemic sclerosis.
Bold values means they are statistically signiﬁcant (P value < .05).

higher odds of a restrictive ventilatory defect with FVC70%
predicted (Table 4). The presence of a restrictive ventilatory
defect was signiﬁcantly associated with cigarette smoking
(Table 4). Notably, patients with dcSSc compared to lcSSc had
approximately equal odds of demonstrating a restrictive
ventilatory defect (Table 4).
30% of patients had evidence of pulmonary hypertension on
echocardiogram or right heart cardiac catheterization. Moreover,
these patients had severe disease with a mean DLCO 42% of
predicted. In multivariate analyses, older age at symptom onset

3.3.3. Pulmonary. More than half of the cohort (66%) had a
restrictive ventilatory defect with FVC 70% of predicted. The
overall mean FVC percent predicted was 63%, and mean DLCO
percent predicted was 49% (Table 2). By report 68% of patients
had pulmonary ﬁbrosis. 43% of patients had evidence of
pulmonary ﬁbrosis on CT chest and 38% of these patients had
a severe restrictive ventilatory defect (FVC 50% predicted)
(Table 2).
Anti-topoisomerase I positivity was associated with signiﬁcantly higher odds of pulmonary ﬁbrosis on CT chest, and 2-fold
5
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Figure 1. Distribution of respective severity scores for organ involvement in the GRASP cohort . Respective severity scores assigned in accordance with the
revised Medsger Severity Score for systemic sclerosis.[24] GRASP = Genome Research in African American Scleroderma Patients cohort.

in age, 95% CI 1.03–1.12). Cigarette smoking was associated
with 88% higher odds of severe cardiac involvement (Table 5).

was signiﬁcantly associated with pulmonary hypertension
(Table 4). Furthermore, a 6% increase in odds of pulmonary
hypertension was noted with each 1 year increase in disease
duration. The diffuse subtype was protective and associated with
41% lower odds of pulmonary hypertension (Table 4).

3.3.5. Gastrointestinal tract. 94% of patients had a history of
gastrointestinal tract involvement of varying severity. In the
adjusted model, anti-RNA polymerase III positivity was
associated with 63% lower odds of gastrointestinal involvement
including gastrointestinal reﬂux, abnormal small bowel series,
small intestinal bacterial overgrowth, malabsorption syndrome,
episodes of pseudo-obstruction or the requirement of total
parenteral nutrition (adjusted OR 0.37, 95% CI 0.14–0.96).
Notably, 11% of patients experienced severe gastrointestinal
complications such as malabsorption syndrome, pseudo-obstruction, or required total parenteral nutrition. The diffuse subtype
was associated with over 2-fold higher odds of severe
gastrointestinal complications (Table 5).

3.3.4. Cardiac. Echocardiographic or electrocardiogram evidence of cardiac disease was noted in 24% of patients. 11% of
patients had a Medsger cardiac severity score of 4, indicative of
either clinical signs of heart failure, a left ventricular ejection
fraction of <30%, an arrhythmia requiring treatment or a heart
transplant (Fig. 1).
In multivariate analyses, a signiﬁcant association was noted
between cardiac involvement and older age at symptom onset
(adjusted OR 1.03 per 1 year increase in age, 95% CI 1.01–1.05),
longer disease duration (adjusted OR 1.05 per year, 95% CI
1.02–1.08), and male sex (adjusted OR 2.00, 95% CI 1.14–3.48).
Moreover, the signiﬁcance of the observed associations was
maintained, even after adjustment for atherosclerotic cardiovascular disease and cardiovascular risk factors including diabetes
mellitus, hypertension, hyperlipidemia, and cigarette smoking.
The odds of severe cardiac involvement increased by 5% per
annum of disease duration (Table 5). The magnitude and
signiﬁcance of this association was maintained in multivariate
analysis adjusting for atherosclerotic cardiovascular disease and
cardiovascular risk factors (adjusted OR 1.07 per 1 year increase

3.3.6. Renal. Normal renal function was noted in 85% of
patients. The prevalence of scleroderma renal crisis (SRC) in the
GRASP cohort was 7% (Table 2). In bivariate analyses, SRC was
signiﬁcantly associated with the diffuse subtype (OR 3.30, 95%
CI 1.68–6.47). Additionally, anti-RNA polymerase III positivity
was associated with more than 4-fold increased odds of SRC (OR
4.03, 95% CI 1.85–8.77). The signiﬁcant association with antiRNA polymerase III positivity, but not diffuse subtype, was
maintained in the adjusted model (Table 4).
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lww.com/MD/C23. 30% of patients were seropositive for antitopoisomerase I while only 8% were anticentromere positive
(Table 2). A low prevalence of anti-RNA polymerase III positivity
(13%) was observed; however, it is important to note that antiRNA polymerase III data were missing in 40% of patients, likely
because this assay was not commercially available until 2007.
A predilection for anti-topoisomerase I positivity was noted in
men, while a signiﬁcantly higher prevalence of anti-centromere
positivity was observed in women (Table 2). A variety of
antinuclear antibody (ANA) patterns were observed, with the
nucleolar pattern being the most common, noted in 36% of
patients (Table 2).

Table 3
Clinical and serological characteristics of the Genome Research in
African American Scleroderma Patients cohort by Scleroderma
subtype.

Sex
Male
Female
Age at symptom onset, mean ± SD
Raynaud’s Phenomenon
Non-Raynaud’s Phenomenon
Disease duration (years), mean ± SD
Maximum mRSS, mean ± SD
Raynaud’s Phenomenon
Telangiectasia
Calcinosis
Organ system involvement
Skeletal muscles
GI tract
Heart
Kidney
SSc Renal Crisis
Pulmonary
FVC% pred, mean ± SD
DLCO% pred, mean ± SD
Pulmonary ﬁbrosis
CXR evidence
CT chest evidence
and FVC 50% pred
Pulmonary Hypertension
ECHO PH
Cath PH
Autoantibodies
Anti-centromere
Anti-topoisomerase I
Anti-RNA polymerase III
Anti-U1 RNP
Anti-U3 RNP
Anti-Th/To
Anti-PmScl
Anti-Smith
Anti-Ro
Anti-La
Anti-dsDNA
Antinuclear
Overlapping autoimmune disease
Rheumatoid arthritis
Systemic lupus erythematosus
Inﬂammatory myopathy
Sjögren’s
Other

Limited SSc
(n = 432)

Diffuse SSc
(n = 566)

52 (12)
380 (88)
38.5 ± 13.7
38.4 ± 13.6
41.1 ± 13.4
12.8 ± 9.9
5±5
420 (98)
222 (52)
78 (18)

112 (20)
454 (80)
39.5 ± 13.6
39.6 ± 13.5
40.3 ± 13.4
7.6 ± 7.0
20 ± 10
547 (98)
279 (50)
104 (19)

.215
.199
.327
<.001
<.001
.958
.506
.892

75 (20)
383 (93)
95 (24)
64 (16)
11 (3)
357 (87)
62.2 ± 21.9
48.0 ± 21.6
243 (69)
38 (14)
160 (47)
65 (42)
142 (35)
92 (22)
92 (22)

160 (35)
512 (95)
125 (25)
76 (15)
45 (9)
473 (89)
62.9 ± 21.0
50.4 ± 21.8
313 (68)
48 (13)
194 (41)
64 (35)
140 (27)
97 (19)
75 (15)

<.001
.113
.890
.578
<.001
.444
.661
.124
.579
.974
.101
.206
.016
.187
.002

P
.001

65
92
19
72
6
4
5
27
74
14
28
384
99
21
39
31
6
9

(18)
(24)
(8)
(22)
(11)
(15)
(10)
(8)
(22)
(4)
(11)
(94)
(23)
(5)
(9)
(7)
(1)
(2)

6
172
60
70
11
1
1
23
63
13
19
505
100
14
25
53
8
7

(1)
(33)
(16)
(16)
(16)
(3)
(2)
(5)
(14)
(3)
(7)
(94)
(18)
(2)
(4)
(9)
(1)
(1)

3.5. Overlapping autoimmune diseases
In total, 1 in 5 patients were diagnosed with an overlapping
autoimmune disease of which systemic lupus erythematosus
(SLE) and inﬂammatory myopathies were the most common
(Table 2). In the multivariate model which also included antiU1RNP positivity, seropositivity for anti-topoisomerase I was
associated with signiﬁcantly lower odds of an overlapping
autoimmune disease (adjusted OR 0.53, 95% CI 0.29–0.96).
Anti-U1RNP positivity was associated with an approximately 4fold higher odds of exhibiting an overlapping autoimmune
disease (adjusted OR 3.99, 95% CI 2.33–6.84).
3.6. Immunosuppressive therapy
A history of exposure to immunosuppressive therapy was
obtained. The immunosuppressive agents administered are
summarized in Table 2. The most commonly prescribed
immunosuppressive agents were prednisone (53%) and mycophenolate mofetil (37%), while cyclophosphamide was used in
13% of patients (Table 2).

<.001
.004
.003
.026
.422
.100
.045
.077
.003
.329
.100
.983
.040
.042
.003
.217
.974
.291

4. Discussion
Our study highlights sociodemographic, clinical and serological
features of the largest multicenter cohort of African American
patients with SSc. It provides insight into the factors associated
with clinically signiﬁcant and severe manifestations of SSc in
African Americans and emphasizes the unique clinical features of
SSc in African Americans that differ from that reported in cohorts
of European ancestry.
The European League Against Rheumatism Scleroderma Trials
and Research (EUSTAR) cohort is the largest multinational
SSc cohort, comprised of over 7000 patients of predominantly
European ancestry.[25] Genetic studies have been conducted using
this cohort to identify SSc disease susceptibility loci.[26–28]
However, patients in the EUSTAR cohort differ in fundamental
clinical characteristics from those enrolled in GRASP. The
inferences made from genetic studies in the EUSTAR and other
cohorts of predominantly European ancestry[29–31] may not be
applicable to African American patients represented in the
GRASP cohort.
The mean age at onset of RP and the ﬁrst non-RP symptom was
39.1 and 40.6 years, respectively, in the GRASP cohort. In
contrast in the EUSTAR cohort, the mean age of onset of RP and
non-RP symptoms occurred 3 and 4 years later, respectively.[25]
This is consistent with prior studies, in which the average age at
onset of SSc-associated symptoms and subsequent diagnosis was
reported to be signiﬁcantly younger in African Americans than
European Americans.[2,10,32–35]

Except where indicated otherwise, values are the number (%) of patients.
CT = computed tomography, DLCO% pred = diffusing capacity of the lung for carbon monoxide
percent of predicted, ECHO = echocardiogram, FVC% pred = forced vital capacity percent of
predicted, mRSS = modiﬁed Rodnan skin score, PH = pulmonary hypertension, SSc = systemic
sclerosis.
Bold values means they are statistically signiﬁcant (P value < .05).

3.3.7. Muscle. 237 (28%) patients had an abnormal muscle
severity score indicating weakness. Patients with dcSSc had a
higher prevalence of skeletal muscle involvement (Table 3).
The diffuse subtype was associated with a 2-fold higher odds
of skeletal muscle involvement compared to limited disease
(adjusted OR 2.00, 95% CI 1.20–3.33).
3.4. Serological proﬁle
Clinical characteristics of the GRASP cohort by the serological
proﬁle are summarized in Supplementary Table 3, http://links.
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Table 4

∗

Factors associated with Clinical Manifestations of Systemic Sclerosis, adjusted odds ratio (95% conﬁdence interval) .
Diffuse
Scleroderma
Age at onset
Disease duration
Male sex
Diffuse SSc
subtype
ACA
Topo I
RNA Pol III
Smoking status

jj †

Telangiectasia

0.99 (0.97–1.00)
0.93 (0.90–0.95)
1.53 (0.91–2.57)
_

0.99
1.04
0.89
1.14

(0.98–1.01)
(1.02–1.07)
(0.56–1.42)
(0.78–1.67)

0.14 (0.05–0.38)
1.67 (1.08–2.58)
2.54 (1.36–4.75)
_

1.47 (0.69–3.12)
0.77 (0.52–1.15)
0.43 (0.24–0.75)
_

Pulmonary
Fibrosis

Calcinosis

¶†

FVC%
pred† 70

Pulmonary
Hypertension

Scleroderma
Renal Crisis

(0.98–1.01)
(1.02–1.08)
(0.39–1.39)
(0.82–2.24)

1.00
1.02
0.80
0.63

(0.99–1.02)
(0.99–1.05)
(0.47–1.36)
(0.41–0.98)

1.00
1.01
1.37
0.91

(0.98–1.02)
(0.98–1.04)
(0.77–2.42)
(0.58–1.41)

1.02‡
1.06
1.53
0.59

(1.00–1.04)
(1.03–1.09)
(0.87–2.69)
(0.37–0.93)

1.01
1.01
1.81
2.45

0.68 (0.25–1.86)
1.57 (0.96–2.57)
1.29 (0.65–2.56)
_

0.45
2.14
1.00
1.41

(0.20–1.05)
(1.38–3.31)
(0.54–1.84)
(0.93–2.14)

0.88
2.05
0.94
1.58

(0.38–2.02)
(1.26–3.33)
(0.50–1.78)
(1.01–2.46)

1.52
1.29
1.22
1.19

(0.71–3.26)
(0.79–2.10)
(0.61–2.45)
(0.75–1.86)

0.53 (0.19–1.49)
2.88 (1.20–6.94)
_

1.00
1.05
0.74
1.36

(0.98–1.05)
(0.96–1.07)
(0.75–4.37)
(0.92–6.47)
x

ACA = anti-centromere, FVC% pred = forced vital capacity percent of predicted, RNA Pol III = anti-RNA polymerase III, SSc subtype = scleroderma subtype, Topo I = anti-topoisomerase I.
∗
Adjusted model includes covariates: sex (male versus female), SSc subtype (diffuse versus limited), autoantibody status (positive versus negative), age at ﬁrst symptom onset and disease duration in years.
†
Covariate of smoking status (ever versus never smoked cigarettes) included in multivariate analysis.
‡
P = .015.
x
In the adjusted model: Scleroderma renal crisis was not noted in anti-centromere antibody seropositive patients.
jj
Pulmonary ﬁbrosis evident on CT chest.
¶
Pulmonary hypertension evident on echocardiogram or right heart cardiac catheterization.
Bold values means they are statistically signiﬁcant (P value < .05).

or the higher seroprevalence of anti-RNA polymerase III in the
GRASP (13% vs 2%) compared to the EUSTAR cohort.[25]
The frequency of anti-topoisomerase I positivity in African
American SSc cohorts is estimated to range from 16% to
39%.[2,8,10,32,33,35,41,42] 30% of patients in the GRASP cohort
were anti-topoisomerase I positive. Interestingly, a slightly higher
prevalence of anti-topoisomerase I positivity (37%) was observed
in the EUSTAR cohort.[25] Additionally, while the prevalence of
anti-RNA polymerase III positivity in the GRASP cohort (13%)
was consistent with prior estimates from other African American
SSc cohorts[32,35,41] it was 6 times higher than that observed in the
EUSTAR cohort (13% vs 2%).[25] This suggests that differences
exist in the serological proﬁles among SSc patients of African and
European ancestry, thereby limiting the generalizability of the
EUSTAR reports.
Anti-centromere antibody positivity was lower (8% vs 32%)
and anti-U1 RNP positivity was higher (18% vs 8%) in the
GRASP compared to EUSTAR cohort.[25] Unfortunately,
serological data on anti-U3 RNP and other nucleolar autoantibodies were not uniformly available for patients in the GRASP
cohort, limiting our ability to make reliable inferences about the
prevalence of these autoantibodies. Anti-U3 RNP antibodies are

Diffuse cutaneous SSc was present in 57% of the GRASP
cohort, in contrast to 37% in the EUSTAR cohort.[25] This is
of particular importance, as patients with dcSSc have more
extensive cutaneous ﬁbrosis affecting the trunk and proximal
limbs, and are noted to exhibit a higher frequency of cardiac,
pulmonary, and renal involvement especially within the ﬁrst
3 years of disease onset.[36]
Pulmonary complications are a prominent source of morbidity
and mortality in SSc[5,37–39] and African ancestry is reported to be
an independent predictor of early pulmonary involvement[6] and
severe pulmonary ﬁbrosis.[35] Compared to the EUSTAR cohort,
participants in the GRASP cohort had a lower mean FVC %
predicted[25] (63% vs 92%). Additionally, 16% of patients in the
GRASP cohort required supplemental oxygen therapy compared
to 3% in the EUSTAR cohort.
Prior to the advent of initiation of angiotensin converting
enzyme (ACE) inhibitors for management of SRC, the 5-year
cumulative survival of patients with this potentially fatal
complication was <10%.[40] The prevalence of SRC in the
GRASP cohort was 3.5 times that observed in the EUSTAR
cohort (7% vs 2%).[25] This difference may potentially be
attributed to the higher frequency of dcSSc in the GRASP cohort
Table 5

∗

Factors associated with Severe Organ Involvement, adjusted odds ratio (95% conﬁdence interval) .
Cutaneous
Age at onset
Disease duration
Male sex
Diffuse SSc
subtype
ACA
Topo I
RNA Pol III
Smoking status

Vascular†

Pulmonary†

Cardiac†

Muscle

Gastrointestinal

(0.92–1.05)
(0.95–1.15)
(0.80–19.35)
(0.33–12.42)

1.01
1.00
0.93
2.11

0.99 (0.96–1.01)
0.95 (0.91–1.00)
1.97 (1.02–3.80)
_

0.97
1.00
0.98
2.28

(0.95–0.98)
(0.98–1.03)
(0.58–1.65)
(1.47–3.52)

1.00
1.01
1.11
0.78

(0.98–1.01)
(0.98–1.03)
(0.67–1.82)
(0.52–1.17)

1.01
1.05
1.83
1.14

(0.99–1.04)
(1.02–1.09)
(0.90–3.73)
(0.59–2.20)

0.98
1.04
3.93
2.01

0.42 (0.05–3.24)
2.09 (1.14–3.86)
3.00 (1.41–6.38)
_

1.47
1.40
0.54
2.01

(0.67–3.23)
(0.91–2.16)
(0.28–1.04)
(1.33–3.06)

0.68
1.25
0.74
1.41

(0.32–1.42)
(0.82–1.90)
(0.41–1.35)
(0.95–2.09)

1.67
0.93
0.29
1.88

(0.63–4.44)
(0.47–1.83)
(0.07–1.23)
(1.04–3.40)

NA‡
0.87 (0.15–5.13)
3.95 (0.67–23.35)
_

(0.99–1.03)
(0.96–1.04)
(0.47–1.84)
(1.13–3.95)

0.79 (0.22–2.86)
1.21 (0.68–2.13)
0.74 (0.31–1.74)
_

Renal
0.98
1.01
2.99
1.45

(0.94–1.03)
(0.94–1.09)
(0.93–9.59)
(0.41–5.18)

NAx
0.62 (0.16–2.41)
2.45 (0.62–9.71)
_

ACA = anti-centromere, RNA Pol III = anti-RNA polymerase III, SSc subtype = scleroderma subtype, Topo I, anti-topoisomerase I.
∗
Adjusted model includes covariates: sex (male versus female), SSc subtype (diffuse versus limited), autoantibody status (positive versus negative), age at ﬁrst symptom onset and disease duration in years.
†
Covariate of smoking status (ever versus never smoked cigarettes) included in multivariate analysis.
‡
In the adjusted model, severe muscle involvement was not noted in anti-centromere antibody seropositive patients.
x
Severe renal disease was not noted in anti-centromere antibody seropositive patients.
Bold values means they are statistically signiﬁcant (P value < .05).
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reported to be highly speciﬁc for SSc and more prevalent in
African Americans,[43,44] exhibiting associations with diffuse
disease, skeletal muscle involvement, and primary pulmonary
arterial hypertension[43,45] as well as aggressive gastrointestinal
disease.[35] Of note anti-U3 RNP antibodies typically demonstrate a nucleolar pattern on indirect immunoﬂuorescence. This
pattern was observed in 36% of the GRASP cohort.
African American patients with SSc are reported to have
overall lower sociodemographic status and signiﬁcantly fewer
years of education than European Americans.[8,10] It is noted that
97% of the GRASP cohort obtained a high school education with
59% completing college or post-graduate education. Furthermore, participants in the GRASP cohort were almost universally
insured, with 97% having Medicare, private insurance or medical
assistance. In light of this, the high disease burden in the GRASP
cohort is unlikely to be substantially attributed to socioeconomic
factors and impaired access to healthcare.
There are limitations to our study, primarily related to missing
data stemming from the retrospective collection of information.
In particular, while DNA samples have been uniformly provided,
for some patients the corresponding clinical and serological
information are incomplete. Nevertheless, the data gleaned from
the GRASP cohort is comprehensive, providing the most
complete phenotypic characterization of SSc in African American
patients to date.
Evidence of distinct clinical and serological differences between
SSc patients of African and European ancestry underscores the
critical importance of further research in African Americans, who
otherwise may not beneﬁt from precision medicine through new
clinical and technological advancements in the treatment of their
disease.[46] Our study highlights sociodemographic, clinical and
serological features of this multicenter cohort of African
American patients and emphasizes the severe disease burden of
SSc in African Americans. Furthermore, GRASP provides a
unique cohort to facilitate future investigations probing the role
of genetic factors in SSc disease susceptibility and severity in
African Americans.

Acknowledgments
The authors would like to thank Gwendolyn Leatherman and
Adrianne Woods for excellent database management support.
They would also like to acknowledge the Martha McCrory
endowment.

References
[1] Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in
Allegheny County, Pennsylvania. A twenty-year study of hospitaldiagnosed cases, 1963–1982. Arthritis Rheum^^ 1997;40:441–5.
[2] Mayes MD, Lacey JVJr, Beebe-Dimmer J, et al. Prevalence, incidence,
survival, and disease characteristics of systemic sclerosis in a large US
population. Arthritis Rheum 2003;48:2246–55.
[3] Mendoza F, Derk CT. Systemic sclerosis mortality in the United States:
1999-2002 implications for patient care. J Clin Rheumatol 2007;13:
187–92.
[4] Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding
the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep 2014;16:411.
[5] Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis,
1972–2002. Ann Rheum Dis 2007;66:940–4.
[6] McNearney T, Reveille JD, Fischbach M, et al. Pulmonary involvement
in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57:318–26.
[7] Silver RM, Bogatkevich G, Tourkina E, et al. Racial differences between
blacks and whites with systemic sclerosis. Curr Opin Rheumatol 2012;
24:642–8.

9

Morgan et al. Medicine (2017) 96:51

Medicine

[38] Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in
systemic sclerosis: an international meta-analysis of individual patient
data. Am J Med 2005;118:2–10.
[39] Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker
of pulmonary involvement in systemic sclerosis? Chest 1999;116:
715–20.
[40] Steen VD, Medsger TAJr. Long-term outcomes of scleroderma renal
crisis. Ann Intern Med 2000;133:600–3.
[41] Krzyszczak M, Li Y, Ross S, et al. Gender and ethnicity differences in the
prevalence of scleroderma-related autoantibodies. Clin Rheumatol
2011;30:1333–9.
[42] Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum
2005;35:35–42.
[43] Okano Y, Steen VD, Medsger TA. Autoantibody to U3 Nucleolar
Ribonucleoprotein (Fibrillarin) in patients with systemic sclerosis.
Arthritis Rheum 1992;35:95–100.
[44] Masataka K, Yutaka O, Junichi K, et al. Racial differences in the
distribution of systemic sclerosis-related serum antinuclear antibodies.
Arthritis Rheum 1994;37:902–6.
[45] Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in
systemic sclerosis. Arthritis Rheum 2009;60:1112–8.
[46] Ramos PS, Silver RM, Feghali-Bostwick CA. Genetics of
systemic sclerosis: recent advances. Curr Opin Rheumatol 2015;27:
521–9.

[30] Lopez-Isac E, Campillo-Davo D, Bossini-Castillo L, et al. Inﬂuence of
TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12
pathway. Ann Rheum Dis 2016;75:1521–6.
[31] Coustet B, Bouaziz M, Dieude P, et al. Independent replication and meta
analysis of association studies establish TNFSF4 as a susceptibility gene
preferentially associated with the subset of anticentromere-positive
patients with systemic sclerosis. J Rheumatol 2012;39:997–1003.
[32] Gelber A, Manno R, Shah A, et al. Race and association with disease
manifestations and mortality in scleroderma: a 20-year experience at
the Johns Hopkins Scleroderma Center and review of the literature.
Medicine 2013;92:191–205.
[33] Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma
among women in Michigan. Arthritis Rheum 1997;40:734–42.
[34] Nashid M, Khanna P, Furst D, et al. Gender and ethnicity differences in
patients with diffuse systemic sclerosis—analysis from three large
randomized clinical trials. Rheumatology 2011;50:335–42.
[35] Steen VD, Domsic R, Lucas M, et al. A clinical and serologic comparison
of African American and Caucasian patients with systemic sclerosis.
Arthritis Rheum 2012;64:2986–94.
[36] Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy.
Clin Exp Rheumatol 2015;33(4 suppl 92):S3–7.
[37] Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or
high dose prednisolone for systemic sclerosis lung disease. J Rheumatol
2002;29:298–304.

10

